Logo-bi
Original Article
Yuri Yu. Shchegolev ORCID, Danila V. Sorokin, Alexander M. Scherbakov* ORCID, Olga E. Andreeva ORCID, Diana I. Salnikova ORCID, Ekaterina I. Mikhaevich ORCID, Margarita V. Gudkova ORCID, Mikhail A. Krasil’nikov ORCID
Bioimpacts. 2023;13(4): 313-321. doi: 10.34172/bi.2023.27490
PMCID: PMC10460766     PMID: 37645026     Scopus ID: 85168127787    
Prolonged cell treatment with mTOR inhibitor rapamycin leads to the development of resistance. Exosomes of resistant cells induce the resistance to rapamycin in the parent MCF-7cells. Exosome-induced resistance reproduces the changes revealed in the rapamycin-resistant cells, including the activation of ERK/AP-1.
Original Article
Zeinab Mazloumi ORCID, Ali Rafat, Khadijeh Dizaji Asl, Mohammad Karimipour, Dariush Shanehbandi, Mehdi Talebi, Majid Montazer, Ali Akbar Movassaghpour, Alireza Dehnad, Raheleh Farahzadi, Hojjatollah Nozad Charoudeh* ORCID
Bioimpacts. 2024;14(4): 27640. doi: 10.34172/bi.2023.27640
PMCID: PMC11298022     PMID: 39104619     Scopus ID: 85198917745    


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge